. Author manuscript; available in PMC: 2015 Dec 30.

Published in final edited form as: Expert Opin Drug Discov. 2014 Dec 9;10(1):17–36. doi: 10.1517/17460441.2014.966680

Table 2.

Summary of the clinical progression of eCB-based drugs tested for the treatment of psychiatric disorders.

TARGET	DRUG	FOR THE TREATMENT OF	CLINICAL PROGRESSION
CB1r/CB2r AGONISTS	Dronabinol	Schizophrenia [83]	Phase IIa
	Dronabinol	Fear extinction [156]	Phase II (completed)
	THC	PTSD [157]	Phase IV
	Nabilone	PTSD (nightmares) [101]	Phase II
	Sativex (THC & CBD)	Cannabis dependence w/ anxiety [158]	Phase I
	Sativex (THC & CBD)	Multiple Sclerosis (cognitive function & mood) [159]	Phase IV
CB1r/CB2r ANTAGONISTS	Cannabidiol (CBD)	Schizophrenia (psychotic symptoms) [160]	Phase II (completed)
CB1r/CB2r ANTAGONISTS	GWP42003 (CBD)	Schizophrenia [84]	Phase II
CB1r ANTAGONIST	AVE-1625	Schizophrenia (cotreatment w/ anti- psychotics) [161]	Phase II (terminated)
FAAH INHIBITORS	URB597	Schizophrenia [162]	Phase I
FAAH INHIBITORS	SSR411298	Major Depressive Disorder [153]	Phase II